Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Key PointsNovo Nordisk unveiled a troubling guidance for 2026, which tanked the stock.It recently reached a deal with telehealth company Hims & Hers Health to sell its GLP-1 products.The stock is trading at just 10 times its earnings.10 stocks we like better than Novo Nordisk › Shares of Danish drugmaker Novo Nordisk (NYSE: NVO) have been in a full-blown tailspin over the past 12 months. The stock has lost more than half of its value as the comp…